Using single-nucleus RNA-sequencing analysis of RGCs from donors with MS and control individuals, it is found that CFH expression was strongly correlated with intrinsic resilience to RGC degeneration and reveals a non-canonical intracellular function of CFH in neurons.
Abstract
Neurodegeneration is a major driver of disability in multiple sclerosis (MS), the most common chronic inflammatory disease of the central nervous system (CNS)1. Retinal ganglion cells (RGCs), a heterogeneous neuronal population in the eye, undergo degeneration in MS and provide a model to study neuronal subtype-specific resilience to inflammatory injury2. However, the neuron-intrinsic mechanisms underlying differential vulnerability remain unclear. Here we identify a neuroprotective role for intracellular complement factor H (CFH) in neurons. Using single-nucleus RNA-sequencing analysis of RGCs from donors with MS and control individuals, we found that CFH expression was strongly correlated with intrinsic resilience to RGC degeneration. Mechanistically, CFH was induced in retinal and other CNS neurons in response to inflammatory and oxidative stress, where it limited reactive oxygen species accumulation and lipid peroxidation. CFH localized to the endoplasmic reticulum, a major site of lipid peroxidation during neuronal ferroptosis. Its protective activity was dependent on its C-terminal SCR20 domain, was independent of CFH secretion and was preserved in the absence of complement component C3. These findings reveal a non-canonical intracellular function of CFH in neurons. Together, our results identify CFH as a key mediator of neuronal resilience across the CNS in mice and humans and provide mechanistic insight into inflammatory neurodegeneration with implications for MS therapy and neuroprotection more broadly. CFH is a key mediator of neuronal resilience across the central nervous system in mice and humans.
Neuroinflammation represents a common pathological mechanism underlying a wide range of central nervous system (CNS) disorders, encompassing neurodegenerative disorders (NDDs), ischemic stroke (IS), traumatic brain injury (TBI), and demyelinating diseases such as multiple sclerosis (MS). This process is initiated by th...
Advanced fluid biomarkers, such as seed amplification assays (SAA), alongside multidimensional neuroimaging techniques (PET, SPECT, MRI), are proving crucial for detecting these early microglial and pathological changes to guide personalized, disease-modifying therapies of PD.
Manuel Debasa-Mouce, Alberto Ouro, J. De Leon et al.· Advances in Immunology· 0 citations
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with complex pathophysiological mechanisms and limited therapeutic options. The identification of key molecular targets that can effectively modulate the multifaceted pathological and reparative processes underlying ischemic stroke is u...
Yu-Jie Zhai, Jia-Qi Jiao, Ze-Yu Wang et al.· Journal of Integrative Neuro...· 0 citations
PAF/PAF-R targeting remains a mechanistically promising but clinically unestablished therapeutic approach requiring further translational investigation, and some detrimental effects of PAF appear to occur independently of PAF-R.
A. Baothman, Hayder M. Al-kuraishy, Weam A. Elkady et al.· Multiple Sclerosis and Relat...· 0 citations
Abstract Cortical neurodegeneration and glial activation are major drivers of disability progression in multiple sclerosis, but the molecular mechanisms underlying these processes remain poorly defined. Members of the NR4A nuclear receptor family are stress-responsive transcription factors that regulate neuronal surviv...
Buse Unlu Kobya, Aimee Avery, G. DeLuca et al.· Brain Communications· 0 citations
This work situates MiET formation within the broader microglial functional repertoire and focuses on how ET-dominant responses may compromise homeostatic or neuroprotective roles, expanding the conceptual framework for microglial pathogenicity and inviting future mechanistic and translational research.
Lipika Sha, Sushmita Jha· Advances in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.